Please assess the completion status of the following clinical trial:

Trial Title: V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* In good health~* 12 to 15 months of age~* Negative clinical history to measles, mumps, rubella, varicella and/or zoster~* Received only the 3-dose primary series of a pneumococcal conjugate vaccine with at least 2 months prior to the receipt of any of the study vaccines~* Signed consent~Exclusion Criteria:~* Previous administration of any measles, mumps, rubella, or varicella vaccine either alone or in any combination~* Any condition resulting in depressed immunity~* Any allergy to any vaccine component as stated in the package circulars~* Exposure to measles, mumps, rubella, varicella, or zoster within 4 weeks prior to the study vaccination~* History of seizure disorder~* Receipt of an inactivated vaccine within 14 days prior to enrollment or live vaccine within 30 days~* Recent febrile illness

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 15 Months
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Group 1: ProQuad™ (V221) + PREVNAR™ (pneumococcal 7-valent conjugate vaccine) followed by ProQuad™ (Day 91)
- 2 (Type: EXPERIMENTAL): Group 2: PREVNAR™ followed by ProQuad™ (Day 43) followed by ProQuad™ (Day 133)
- 3 (Type: EXPERIMENTAL): Group 3: ProQuad™ followed by PREVNAR™ (Day 43), followed by ProQuad™ (Day 91)

Based on this trial design, predict the completion outcome and termination type (if applicable).